Overview

A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
0
Participant gender:
All
Summary
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection. In addition to this, we will be looking at the comparison of the effects (good and bad) of LdT and lamivudine.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Lamivudine
Telbivudine
Criteria
Patients with chronic hepatitis b with evidence of cirrhosis, who are at least 18 to 70
years old, may be eligible to participate in this study.